Literature DB >> 7173292

Acute and long-term hypotensive effects and plasma concentrations of nifedipine in patients with essential hypertension.

K Aoki, K Sato, Y Kawaguchi, M Yamamoto.   

Abstract

The acute and long-term hypotensive effects of low doses of nifedipine, and the correlation between the fall in the blood pressure (BP) and the plasma nifedipine concentration, were investigated in patients with essential hypertension. The oral administration of nifedipine 5 mg rapidly decreased BP from 163 +/- 22/101 +/- 10 to 127 +/- 12/82 +/- 9 mmHg (mean +/- SD; p less than 0.001), and increased heart rate from 72 +/- 8 to 76 +/- 6 beats/min (p less than 0.05), plasma renin activity rose from 1.2 +/- 0.6 to 1.4 +/- 0.8 ng/ml/h (p less than 0.05), and plasma nifedipine concentration was 75.6 +/- 22.0 ng/ml 30 min after administration (n = 7). The nifedipine concentration was significantly correlated both with the fall in BP (r = 0.410, p less than 0.02, n = 31) and the rise in the heart rate (r = 0.412, p less than 0.02, n = 31). Treatment with nifedipine 5 mg t.d.s. alone or in combination either with propranolol 10 mg t.d.s., or thiazide 1 tablet daily, or propranolol and thiazide, controlled BP in 36 patients during the 22 week study period. During the long-term nifedipine therapy, the plasma nifedipine level was significantly correlated with the fall in systolic (r = 0.577, p less than 0.01, n = 20) and diastolic (r = 0.595, p less than 0.01, n = 20) BP. It was concluded that the plasma nifedipine concentration could be correlated with the fall in BP, and that low doses of nifedipine, either as monotherapy or in combination, were effective in the acute and long-term treatment of patients with essential hypertension.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7173292     DOI: 10.1007/bf00547553

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

Review 1.  Vasodilator drugs in the treatment of hypertension.

Authors:  J Koch-Weser
Journal:  Arch Intern Med       Date:  1974-06

2.  Treatment of essential hypertension with a new vasodilator in combination with beta-adrenergic blockade.

Authors:  E Gilmore; J Weil; C Chidsey
Journal:  N Engl J Med       Date:  1970-03-05       Impact factor: 91.245

3.  Antihypertensive effect of cardiovascular Ca2+-antagonist in hypertensive patients in the absence and presence of beta-adrenergic blockade.

Authors:  K Aoki; S Kondo; A Mochizuki; T Yoshida; S Kato; K Kato; K Takikawa
Journal:  Am Heart J       Date:  1978-08       Impact factor: 4.749

4.  Acute and chronic effects of nifedipine in arterial hypertension.

Authors:  O L Pedersen; E Mikkelsen
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

5.  [Electromechanical uncoupling of vascular smooth muscle as the basic principle of coronary dilatation by 4-(2'-nitrophenyl-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester (BAY a 1040, Nifedipine). 1. The significance of Ca ++ ions for the bioelectrical and mechanical activity of smooth muscle].

Authors:  G Grün; A Fleckenstein
Journal:  Arzneimittelforschung       Date:  1972-02

6.  Nifedipine, a new antihypertensive with rapid action.

Authors:  M Guazzi; M T Olivari; A Polese; C Fiorentini; F Magrini; P Moruzzi
Journal:  Clin Pharmacol Ther       Date:  1977-11       Impact factor: 6.875

7.  Hypotensive action and increased plasma renin activity by Ca2+ antagonist (Nifedipine) in hypertensive patients.

Authors:  K Aoki; T Yoshida; S Kato; K Tazumi; I Sato
Journal:  Jpn Heart J       Date:  1976-07

8.  Treatment of hypertension with nifedipine, a calcium antagonistic agent.

Authors:  M T Olivari; C Bartorelli; A Polese; C Fiorentini; P Moruzzi; M D Guazzi
Journal:  Circulation       Date:  1979-05       Impact factor: 29.690

9.  Different antihypertensive effects of nifedipine in conscious experimental hypertensive and normotensive rats.

Authors:  H Ishii; K Itoh; T Nose
Journal:  Eur J Pharmacol       Date:  1980-05-30       Impact factor: 4.432

10.  Antihypertensive effect of (4-2'-nitrophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarbonic acid dimethylester (Nifedipine, Bay-a 1040), a new coronary dilator.

Authors:  M Murakami; E Murakami; N Takekoshi; M Tsuchiya; T Kin
Journal:  Jpn Heart J       Date:  1972-03
View more
  13 in total

Review 1.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

3.  The effects of food and posture on the pharmacokinetics of a biphasic release preparation of nifedipine.

Authors:  V Challenor; D G Waller; B S Gruchy; A G Renwick; C F George; E T McMurdo; J McEwen
Journal:  Br J Clin Pharmacol       Date:  1986-11       Impact factor: 4.335

Review 4.  The management of hypertension.

Authors:  B N Prichard; C W Owens
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

5.  Food and nifedipine pharmacokinetics.

Authors:  V F Challenor; D G Waller; B S Gruchy; A G Renwick; C F George
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

6.  Plasma nifedipine levels and fall in blood pressure in a 53 year old woman.

Authors:  F Pasanisi; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Determination of (+)- and (-)-nicardipine concentrations in human serum and their correlation with the antihypertensive effect after oral administration of racemic nicardipine.

Authors:  T Iwaoka; N Inotsume; J Inoue; S Naomi; Y Okamoto; S Higuchi; M Nakano; T Umeda
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 8.  Nifedipine. Relationship between pharmacokinetics and pharmacodynamics.

Authors:  C H Kleinbloesem; P van Brummelen; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

Review 9.  Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.

Authors:  H Echizen; M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

10.  Hypotensive effects of diltiazem to normals and essential hypertensives.

Authors:  K Aoki; K Sato; S Kondo; M Yamamoto
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.